Table 1.
Characteristic of included studies.
| Author/NCT number | Blinding setting | Study period(weeks) | Interventions | Sample N/F/M | Mean age(years) | BaselineHbA1c(%) | BaselineWeight(kg) | BaselineBMI(kg/m2) |
|---|---|---|---|---|---|---|---|---|
| NCT00658021 | double blind | 28 | Exenatide –5mcg |
42/31/11 | 14 ± 1.91 | 6.5-10.5 | – | – |
| Exenatide–10 mcg | 38/22/16 | – | – | |||||
| Placebo | 42/29/13 | – | – | |||||
| NCT01204775 | double blind | 16 | Saxagliptin +Metformin |
4/1/3 | 10-17 | 7-10.5 | – | – |
| Placebo | 4/3/1 | – | – | |||||
| NCT01434186 | double blind | 16 | Saxagliptin+Metformin | 4/4/0 | 10-17 | 7-10.5 | – | – |
| Metformin | 2/2/0 | – | – | |||||
| NCT01554618 | double blind | 24 | Exenatide–2 mcg | 58/31/27 | 15.1 ± 1.84 | 6.5-12 | – | – |
| Placebo | 24/17/7 | – | – | |||||
| Jones KL, 2002 (25) | double blind | 8 | Metformin | 42/30/12 | 13.9 ± 1.8 |
8.3 ± 1.3 |
92.8 ± 31.8 |
34.2 ± 10.6 |
| Placebo | 40/27/13 | 13.6 ± 1.8 |
9.0 ± 1.4 |
90.3 ± 38.1 |
33.9 ± 12.7 |
|||
| Gottschalk M, 2007 (16) | single blind | 24 | Glimepiride | 132/88/44 | 13.8 ± 2.3 |
8.53 ± 1.58 |
82.60 ± 25.60 |
31.57 ± 8.48 |
| Metformin | 131/87/44 | 83.83 ± 27.47 |
31.60 ± 8.17 |
|||||
| David J Klein, 2014 (24) | double blind | 5 | Liraglutide | 14/9/5 | 14.4 | 8.3 | 112.7 | 40.0 |
| Placebo | 7/5/2 | 15.6 | 7.8 | 114.2 | 39.9 | |||
| William V Tamborlane, 2018 (23) | double blind | 12 | Linagliptin–1 mg | 10/4/6 | 14.0 ± 1.9 |
7.86 ± 0.95 |
79.8 ± 22.2 |
30.3 ± 6.8 |
| Linagliptin–5 mg | 14/9/5 | |||||||
| Placebo | 15/8/7 | |||||||
| Tamborlane WV, 2019 (26) | double blind | 26 | Liraglutide+Metformin | 66/41/25 | 14.57 ± 1.72 |
7.78 ± 1.34 |
91.5 ± 26.8 |
33.9 ± 9.25 |
| Metformin | 68/42/26 | |||||||
| Tamborlane WV, 2022 (29) | double blind | 24 | Dapagliflozin | 39/24/15 | 16.0 ± 3.3 |
6.5-11 | 90.7 ± 28.5 |
32.4 ± 8.1 |
| Placebo | 31/19/12 | |||||||
| Jalaludin MY, 2022 (27) | quadruple | 20 | Sitagliptin+Metformin | 62/41/21 | 14.4 ± 1.9 |
8.0 ± 1.1 |
81.9 ± 25.4 |
31.2 ± 8.1 |
| Metformin | 62/40/22 | 79.8 ± 24.8 |
30.6 ± 8.5 |
|||||
| Sitagliptin+MetforminXR | 45/32/13 | 81.9 ± 25.4 |
31.2 ± 8.1 |
|||||
| MetforminXR | 51/32/19 | 79.8 ± 24.8 |
30.6 ± 8.5 |
|||||
| Shankar RR, 2022 (28) | double blind | 20 | Sitagliptin | 95/54/41 | 14.0 ± 2.0 |
7.5 ± 1.04 |
89.1 ± 25.3 |
33.3 ± 7.7 |
| Placebo | 95/61/34 | 81.9 ± 24.8 |
31.2 ± 7.7 |
Except where indicated, data are presented as mean ± SD or minimum–maximum.
N/F/M, Number Analyzed/Female/Male; BMI, body mass index.